Targeting angiogenesis in gynecologic cancers

Hematol Oncol Clin North Am. 2012 Jun;26(3):543-63, viii. doi: 10.1016/j.hoc.2012.01.009.

Abstract

Gynecologic malignancies carry an estimated incidence of 83,750 cases per year and estimated mortality rate of more than 27,000 women per year. New therapies and therapeutic approaches are needed to improve the outlook for women with gynecologic cancers. Recent insights at the molecular and cellular levels are paving the way for a more directed approach to target mechanisms driving tumorigenesis. This article reviews the roles of new and emerging antiangiogenesis drugs, summarizes the data obtained from clinical trials of antiangiogenic agents, and discusses trials under way to address the role of such strategies in gynecologic cancers.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Female
  • Genital Neoplasms, Female / blood supply*
  • Genital Neoplasms, Female / drug therapy*
  • Genital Neoplasms, Female / pathology
  • Humans
  • Neovascularization, Pathologic / drug therapy

Substances

  • Angiogenesis Inhibitors